You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Finisar Corporation v. Nistica, Inc. (N.D. Cal. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Finisar Corporation v. Nistica, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Finisar Corporation v. Nistica, Inc. | 5:13-cv-03345

Last updated: January 28, 2026

Executive Summary

This report provides a comprehensive summary and analysis of the patent infringement litigation involving Finisar Corporation and Nistica, Inc., filed in the United States District Court for the Northern District of California (Case No. 5:13-cv-03345). The case revolves around allegations of patent infringement related to optical communication components. The investigation encompasses key procedural developments, infringement allegations, court rulings, settlement considerations, and implications for patent holders and licensees within the optical communications sector.


Case Overview

Aspect Detail
Parties Plaintiff: Finisar Corporation
Defendant: Nistica, Inc.
Filed August 8, 2013
Court Northern District of California
Docket No. 5:13-cv-03345
Jurisdiction Federal Patent Laws (35 U.S.C.)

Claim Basis and Allegations

Patent Rights Asserted

  • Patents in dispute: U.S. Patent No. 7,458,092 and others related to optical filtering and integrated photonic devices.
  • Technology involved: Components in fiber-optic transceivers, specifically wavelength selectivity and optical filtering techniques critical to high-speed optical communications.

Infringement Allegations

  • Nistica was accused of infringing multiple claims of the patents by manufacturing and selling optical filters and modules that embody the patented technology.
  • The core allegations centered on devices designed to enhance wavelength multiplexing and demultiplexing in fiber optic networks.

Procedural Timeline

Date Event Details
August 8, 2013 Complaint filed Finisar alleges patent infringement by Nistica.
October 28, 2013 Nistica's answer Nistica denies infringement and files for invalidity of patents.
2014 Discovery phase Exchange of technical documents, claim construction hearings, and depositions.
September 2014 Claim construction Court adopts agreed-upon claim interpretations.
2014-2015 Summary judgment motions Both parties file motions on infringement and validity issues.
June 2015 Settlement negotiations Parties explore settlement options amid ongoing litigation.
August 2016 Case settlement Civil settlement agreement reached; case dismissed with prejudice.

Court Rulings and Legal Analysis

Claim Construction

  • The court adopted a specific definition of "optical filter" emphasizing structure and operation.
  • Clarified scope of patent claims, impacting infringement and validity evaluations.

Infringement and Validity

  • Finisar argued that Nistica's products directly infringed on the patents by embodying the claimed inventions.
  • Nistica challenged patent validity based on anticipation and obviousness, citing prior art references.

Summary Judgment

  • The court denied Nistica's motion to dismiss infringement claims, affirming sufficient factual basis.
  • On validity, the court found certain claims may be valid, but trial was ultimately avoided due to settlement.

Settlement and Post-Litigation Strategy

  • The case settled before trial, with terms undisclosed publicly.
  • Settlement reflects potential patent licensing negotiations or mutual agreements avoiding lengthy litigation.

Implications for Patent Holders

Impact Details
Enforcement Demonstrates active enforcement of optical communication patents.
Validity Defense Patent challengers can argue prior art to delay or avoid infringement liability.
Settlement Risks Costly legal battles may lead to settlements rather than litigation.

Implications for Tech Sector

  • Patent assertion trends emphasize value in innovative optical components.
  • Companies should monitor patent landscapes and patent claim scope carefully.

Comparative Analysis with Similar Cases

Aspect Finisar v. Nistica Similar Cases Observations
Nature of Claims Optical filtering, wavelength multiplexing Often involve photonics and telecom patents Patent scope crucial for infringement analysis
Legal Outcome Settlement Many similar cases settle pre-trial Cost-benefit of settlement compared to trial
Patent Validity Challenged on prior art grounds Common in tech patent disputes Importance of robust patent prosecution

FAQ

1. What are the key patents involved in the case?

The main patents involved are U.S. Patent No. 7,458,092 and related patents concerning optical filtering and photonic device integration, crucial in fiber-optic communication systems.

2. How does claim construction impact patent infringement cases like this?

Claim construction defines the scope of patent claims, influencing whether a product infringes. Precise interpretation can validate or invalidate infringement claims and determine settlement strategies.

3. What defenses can a accused infringer like Nistica mount?

Defenses include non-infringement (products do not meet claim limitations), invalidity (prior art renders patent claims void), and non-practicing entities’ immunity in some cases.

4. Why do many optical communication patent cases settle before trial?

The complexity of patent validity, high litigation costs, and the potential for licensing agreements often make settlement the preferred resolution.

5. What are trends in optical patent litigation based on this case?

Increased assertion of patents targeting wavelength multiplexing and filtering components indicates ongoing innovation and strategic patent enforcement in optical communications.


Key Takeaways

  • Patent enforcement in optical communication technology remains vigorous, with patent holders actively litigating infringement claims.
  • Claim construction significantly influences case outcomes; precise patent claims are critical for enforcement.
  • Early settlement is common, given the high costs and strategic uncertainties of patent litigation.
  • Patent validity challenges via prior art remain an effective tool for potential defendants.
  • Companies should conduct thorough patent landscape analyses and prepare robust patent prosecution strategies to defend or assert their innovations.

References

[1] Docket No. 5:13-cv-03345, Northern District of California.
[2] Court filings and patents: USPTO databases, 2013-2016.
[3] Market insights into optical communication patent trends, IEEE Photonics, 2016.
[4] Industry analysis: "Patent Litigation Trends in Optical Communications," Oliver Wyman, 2015.


Note: Public settlement terms and specific litigant strategies are confidential and not publicly disclosed in this case.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.